Literature DB >> 25073463

Radiologic and clinicopathologic findings of peripheral primitive neuroectodermal tumors.

Lei Ba1, Hongna Tan2, Huijuan Xiao3, Yansheng Guan4, Jianbo Gao3, Xianzheng Gao5.   

Abstract

BACKGROUND: Primitive neuroectodermal tumors (PNETs) constitute a rare type of malignant neuroectodermal tumors that have chromosomal translocations identical to Ewing's sarcoma (ES), and the characteristics of this disease remain unclear.
PURPOSE: To describe the clinical, radiological, and pathological features of peripheral PNETs (pPNETs) to enhance their recognition.
MATERIAL AND METHODS: The clinical, imaging, and pathologic findings of 35 patients with pPNETs were retrospectively reviewed, all being confirmed by biopsy or surgical pathology. All 35 patients had preoperative computed tomography (CT) examinations; 10 patients had preoperative magnetic resonance imaging (MRI) studies.
RESULTS: Of 35 pPNET patients, 54.3% had a primary tumor in soft tissue, the others in bone. On plain CT images, 33 lesions demonstrated heterogeneous hypodense masses with multiple lamellar lower density, and with osteolytic destruction if the tumor originated in bone. Calcification was only found in five lesions arising in soft tissue. All lesions enhanced heterogeneously with varying areas of cystic changes, and all lesions in bone and 52.6% of lesions in soft tissue showed ill-defined margins after contrast administration. On MRI, these tumors appeared in conjunction with osteolytic bone destruction and irregular soft tissue masses iso- to hypointense to skeletal muscle on T1-weighted images and showed heterogeneously high intensity on T2-weighted images. All lesions enhanced heterogeneously with cystic changes. Homer-Wright rosettes were observed in 15 lesions, and 97.1% lesions were positive for CD99 in histopathological results.
CONCLUSION: pPNETs can involve any part of the body, and a large, ill-defined, aggressive soft tissue mass and heterogeneous enhancement with or without osteolytic bone destruction on CT or MR images could suggest the diagnosis. © The Foundation Acta Radiologica 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  Peripheral primitive neuroectodermal tumor (pPNET); computed tomography (CT); magnetic resonance imaging (MRI); pathology

Mesh:

Substances:

Year:  2014        PMID: 25073463     DOI: 10.1177/0284185114539321

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  6 in total

1.  Primitive neuroectodermal tumor of the kidney: A rare case with unusual presentation.

Authors:  Kavita Sahai; Mayuri Jain; S C Dash; G P S Gahlot
Journal:  Med J Armed Forces India       Date:  2018-10-15

2.  Imaging findings of adrenal primitive neuroectodermal tumors: a series of seven cases.

Authors:  Y Zhang; P Cai; M Chen; X Yi; L Li; D Xiao; W Liu; W Li; Y Li
Journal:  Clin Transl Oncol       Date:  2016-11-23       Impact factor: 3.405

3.  Triple-phase 99mTc-3P-RGD2 imaging of peripheral primitive neuroectodermal tumor in the hip muscle group with bone metastasis.

Authors:  Jingjing Fu; Jinhua Song; Youcai Zhao; Feng Wang; Guoqiang Shao
Journal:  Mol Clin Oncol       Date:  2016-12-28

4.  Primitive Neuroectodermal Tumour Invading the Inferior Vena Cava.

Authors:  Ali Mir; Marzieh Lashkari; Fatemeh Jafari; Behnam Molavi
Journal:  Eur J Case Rep Intern Med       Date:  2020-04-07

5.  Primary Renal Primitive Neuroectodermal Tumor/Ewing's Sarcoma Imaging and Pathologic Findings of a Patient with a Nine Year, Eight Month Disease Free Period: Case Report and Review of Literature.

Authors:  Ivan Zokalj; Jasminka Igrec; Antonio Plesnar
Journal:  Nephrourol Mon       Date:  2016-07-18

6.  Radiological features of primitive neuroectodermal tumors in intra-abdominal and retroperitoneal regions: A series of 18 cases.

Authors:  Xiaoping Yi; Wenguang Liu; Youming Zhang; Desheng Xiao; Hongling Yin; Xueying Long; Li Li; Hongyan Zai; Minfeng Chen; Wenzheng Li; Lunquan Sun
Journal:  PLoS One       Date:  2017-03-20       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.